Niacin 500 mg

Niacin 500 mg

21st Century4.5 (1,974 ratings)
Format:Tablet Quantity: 100 Tablet(s) · 100 servings
Goals
$8.99 $0.08 per serving
iHerbLowest$8.99Amazon$8.99

About this product

The single-ingredient tablet delivers a very large amount of niacin. If it is nicotinic acid, the serving may affect lipid markers, but that does not make it broad heart support.

The label does not disclose the chemical form or release profile. Those omissions prevent a sound assessment of flushing, liver exposure, and relevance to skin or cardiovascular goals.

It is not a casual daily supplement and fits only a carefully supervised, form-confirmed use case. People seeking niacinamide for skin support should choose a clearly labeled niacinamide product instead.

Who is it for
  • Clinician-guided users after form confirmation
  • Adults with a specific reason for pharmacologic niacin
  • People able to monitor tolerance and laboratory markers
Best for
  • Potential lipid-focused use if confirmed as nicotinic acid
  • Single-ingredient supplementation
  • Short-term supervised trials

Pros

  • Large active amount
  • Simple formula
  • Low cost per serving

Cons

  • Chemical form is not identified
  • No release-control details
  • Poor fit for routine skin support

Warnings

  • If supplied as nicotinic acid, intense flushing, warmth, itching, or dizziness may occur
  • Regular high-dose use can affect liver enzymes, glucose, and uric acid
  • Do not combine with other high-dose niacin products
  • Use for lipid management only with appropriate clinical supervision

Product analysis

77 out of 100
A very high and inexpensive niacin dose with inadequate form and release disclosure; it is unsuitable for casual use and needs clinical oversight if used for lipids.

AI assessment of the formula, label and price. How scoring works

Nutrient quality68

Vitamin B3 is supplied at a meaningful amount in a simple formula. The unidentified form limits assessment of absorption, flushing risk, and suitability for the intended use.

Ingredient transparency80

Most stated amounts and the serving size are clear without a conventional proprietary blend. Form ambiguity, overlapping entries, or missing non-active ingredients leave important label gaps.

Customer satisfaction70

The average rating is strong, with a large review count supporting the signal. No detailed reviews are supplied to assess repeated complaints or intended-use experiences.

Value for money91

The long supply offers good cost efficiency for a single nutrient. The high amount and unidentified form make it less suitable for routine use.

Format
Tablet
Container
100 Tablet(s)
Per serving
$0.08
Also available
Niacin 100 mgB3 100 mg • 110 Tablet(s) • 110 servings$4.99
Customer rating
4.5 · 1,974 ratings
Report analysis

Goals

Cardiovascular Support
Cardiovascular Support
Impact
High effect
A+ Ingredient FitD+ PathwaysB- EvidenceA+ Formulation Logic
Niacin · 500 mg

Niacin 500 mg lists niacin as its only relevant active, and the supplied marker evidence links it to triglyceride metabolism. The declared amount gives full support along that route, but the product covers no other cardiovascular pathway. Its evidence ceiling remains below the goal's highest, and the label does not specify a niacin form.

How this product is rated for Cardiovascular Support

Ingredient fit96

Niacin is the only relevant active listed, with no unrelated ingredients in the saved facts.
Goal fit
The formula is focused on niacin, though it is linked to several goals.
Dose adequacy
The declared amount reaches full dose support in the saved reference curve.

Pathways53

The clearest pathway is triglyceride metabolism; other cardiovascular routes are not covered.
Depth
Triglyceride metabolism is the single strongest covered route.
Breadth
Only one of the target pathways has enough coverage.

Evidence74

The relevant marker evidence is for nicotinic acid, and its evidence ceiling is below the goal's highest.
Evidence strength
Niacin is the strongest ingredient here, but its evidence ceiling does not reach the goal's top.
Studied preparation
The effective ingredient is matched to a preparation represented in research.

Formulation logic100

The single credited ingredient needs no partner, and no conflict was identified.
Partner coverage
Niacin can work alone under the supplied evidence.
Conflicts
No applicable conflict was identified in the saved facts.
Effective doses
The declared amount clears the minimum dose reference.
Study evidence
Niacin Supportive 136 studies
Heart Health
Heart Health
Impact
Moderate effect
A+ Ingredient FitF PathwaysC EvidenceA+ Formulation Logic
Study evidence
Niacin Supportive 105 studies

Ingredients

IngredientAmount per servingScore
Niacin
500 mg 37
Gluten Free Adults 18–50
Report overview
Niacin · 500 mg OverallScore37
F Active Ingredient Quality & BioavailabilityF Dose, Safety & Label TransparencyD- Value
Niacin 500 mg states a large amount, but the available information does not identify its form. That leaves its form-specific dose fit and flushing guidance uncertain. The serving cost is low, though the source detail is incomplete.
How this ingredient is rated

Active Ingredient Quality & Bioavailability36

The available information names no specific niacin form, so its fit with the stated product context and its source quality remain uncertain.
Niacin Form & Goal Alignment
The form is not identified, so its match to the stated context is unclear.
Precursor Source Quality
The available facts do not name a specific niacin source.

Dose, Safety & Label Transparency37

The amount is stated, but the form needed to interpret its dose and flushing guidance is unknown.
Clarity of Chemical Form
The available information lists niacin but does not name its specific form.
Form-Specific Dosage Efficacy
Without the form, the listed 500 mg cannot be matched to a form-specific dose range.
Flush Risk & Safety Labeling
The form is unknown, and the saved facts show no flushing warning, so its applicability is unclear.

Value40

The serving cost is low, but the niacin form is unspecified.
Price Per Effective Serving
The serving cost is low, though the source form is unknown.
View ingredientView products
Loading alternative details
82 Performance

Sustained-Release Niacin with niaXtend 500 mg

Doctor's Best

Sustained-release nicotinic acid provides a clearly identified cardiovascular-focused amount with controlled delivery. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, high-dose niacin can still affect the liver and requires explicit safety guidance.

80 Performance

Niacin (Vitamin B3) 500 mg

Solgar

Clearly identified nicotinic acid provides direct high-dose vitamin B3 coverage with strong cardiovascular alignment. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, the amount may cause flushing and can affect the liver, glucose, or blood pressure.

79 Performance

Niacin-Time 500 mg

Carlson

Timed-release nicotinic acid provides a transparent cardiovascular-focused dose in a long-supply format. Compared with the original, it provides clearer form disclosure or a more purposeful match for cardiovascular-focused niacin use; however, controlled delivery does not remove flushing or liver-related concerns from high-dose niacin.

86 Budget

Niacinamide B-3 100 mg

Source Naturals

A clearly identified moderate niacinamide tablet offers simple non-flushing vitamin B3 support with excellent serving economics. Serving cost is lower than the original, but it does not provide nicotinic acid’s lipid-focused effects and complete excipient details are missing.

82 Budget

Niacin 100 mg

Nature's Way

Clearly identified nicotinic acid supplies a modest, inexpensive vitamin B3 serving with direct form transparency. Serving cost is lower than the original, but immediate release can still cause temporary flushing and the dose is not intended for intensive cardiovascular use.

82 Budget

Niacin 100 mg

Bluebonnet

Clearly identified nicotinic acid provides a meaningful low-dose option in a simple long-supply capsule. It is among the lowest-cost supplied choices, although it does not undercut the already inexpensive original, but noticeable flushing remains possible and people sensitive to liver, glucose, or blood-pressure effects should choose carefully.

80 Value

Niacin 50 mg

Carlson

A clearly named low-dose nicotinic acid tablet provides economical and easy-to-assess vitamin B3 support. Its quality-adjusted serving economics and clearer active design support practical value compared with the original, although the amount is too low for focused cardiovascular use and can still cause flushing.

85 Value

Niacin 100 mg

Source Naturals

A moderate niacinamide tablet provides clearly identified vitamin B3 without typical nicotinic-acid flushing. Its lower serving cost and clearer active design support practical value compared with the original, although the form is intended for nutritional or skin support rather than lipid-focused effects.

80 Value

No-Flush Niacin (Inositol Hexanicotinate) 500 mg

Solgar

Clearly identified inositol hexanicotinate supports a comfort-focused no-flush approach with good serving value. Its quality-adjusted serving economics and clearer active design support practical value compared with the original, although the form is less direct than nicotinic acid for cardiovascular purposes.

Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  2. Role of Niacin in Current Clinical Practice: A Systematic Review.
    Garg A; Sharma A; Krishnamoorthy P; Garg J; Virmani D; Sharma T; Stefanini G; Kostis JB; Mukherjee D; Sikorskaya E · The American journal of medicine · 2017
    Meta-analysis35,206 participants13 studies pooledHeart Health forNiacin
  3. Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes).
    Guyton JR; Slee AE; Anderson T; Fleg JL; Goldberg RB; Kashyap ML; Marcovina SM; Nash SD; O'Brien KD; Weintraub WS; Xu P; Zhao XQ; Boden WE · Journal of the American College of Cardiology · 2013
    Randomized trial3,414 participantsHeart Health Cardiovascular Support forNiacin
  4. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
    D'Andrea E; Hey SP; Ramirez CL; Kesselheim AS · JAMA network open · 2020
    Meta-analysis35,760 participants17 studies pooledHeart Health forNiacin
  5. Exploring the Cardiovascular Impacts of Oral Nicotinamide: A Comprehensive Narrative Review.
    Shoukfeh R; Tisack AM; Lim HW; Mohammad TF · Journal of drugs in dermatology : JDD · 2025
    Narrative reviewHeart Health forNiacin
  6. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  7. Niacinamide: A B vitamin that improves aging facial skin appearance.
    Bissett DL; Oblong JE; Berge CA · Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2005
    Randomized trial50 participantsSkin Health forNiacin
  8. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer.
    Hakozaki T; Minwalla L; Zhuang J; Chhoa M; Matsubara A; Miyamoto K; Greatens A; Hillebrand GG; Bissett DL; Boissy RE · The British journal of dermatology · 2002
    Randomized trial138 participantsSkin Health forNiacin
  9. Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis.
    Mainville L; Smilga AS; Fortin PR · Journal of cutaneous medicine and surgery · 2022
    Meta-analysis3,039 participants29 studies pooledSkin Health forNiacin
  10. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
    Allen NC; Martin AJ; Snaidr VA; Eggins R; Chong AH; Fernandéz-Peñas P; Gin D; Sidhu S; Paddon VL; Banney LA; Lim A; Upjohn E; Schaider H; Ganhewa AD; Nguyen J; McKenzie CA; Prakash S; McLean C; Lochhead A; Ibbetson J; Dettrick A; Landgren A; Allnutt KJ; Allison C; Davenport RB; Mumford BP; Wong B; Stagg B; Tedman A; Gribbin H; Edwards HA; De Rosa N; Stewart T; Doolan BJ; Kok Y; Simpson K; Low ZM; Kovitwanichkanont T; Scolyer RA; Dhillon HM; Vardy JL; Chadban SJ; Bowen DG; Chen AC; Damian DL · The New England journal of medicine · 2023
    Randomized trial158 participantsSkin Health forNiacin
  11. Evaluation of anti-wrinkle effects of a novel cosmetic containing niacinamide.
    Kawada A; Konishi N; Oiso N; Kawara S; Date A · The Journal of dermatology · 2008
    Randomized trial30 participantsSkin Health forNiacin
  12. A Foodborne Outbreak Traced to Niacin Overenrichment.
    Hudson PJ; Vogt RL · Journal of food protection · 2023
    Case-control study21 participantsSkin Health forNiacin
  13. Nicotinamide for Skin Cancer Chemoprevention.
    Breglio KF; Knox KM; Hwang J; Weiss R; Maas K; Zhang S; Yao L; Madden C; Xu Y; Hartman RI; Wheless L · JAMA dermatology · 2025
    Cohort study33,822 participantsSkin Health forNiacin
  14. Chemoprevention of keratinocyte carcinomas and actinic keratoses in adults who were immunocompetent: a systematic review.
    Susanto A; Morgan E; Lindsay D; Collins LG · Clinical and experimental dermatology · 2026
    Systematic review7,355 participants11 studies pooledSkin Health forNiacin
  15. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  16. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  17. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
    Philpott AC; Hubacek J; Sun YC; Hillard D; Anderson TJ · Atherosclerosis · 2013
    Randomized trial66 participantsCardiovascular Support forNiacin
  18. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar.
    Jenkins DJA; Spence JD; Giovannucci EL; Kim YI; Josse RG; Vieth R; Sahye-Pudaruth S; Paquette M; Patel D; Blanco Mejia S; Viguiliouk E; Nishi SK; Kavanagh M; Tsirakis T; Kendall CWC; Pichika SC; Sievenpiper JL · Journal of the American College of Cardiology · 2021
    Meta-analysisCardiovascular Support forNiacin
  19. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial.
    Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA · JAMA · 2000
    Randomized trial468 participantsCardiovascular Support forNiacin
  20. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  21. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  22. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  23. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  24. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  25. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin